Premium
The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases
Author(s) -
Chitra Selvarajan,
Nalini Ganesan,
Rajasekhar Gopalakrishnan
Publication year - 2012
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/j.1756-185x.2012.01737.x
Subject(s) - proteasome , medicine , proinflammatory cytokine , ubiquitin , cancer research , arthritis , inflammation , immunology , microbiology and biotechnology , biology , biochemistry , gene
Abstract In eukaryotes the ubiquitin proteasome pathway plays an important role in cellular homeostasis and also it exerts a critical role in regulating a wide variety of cellular pathways, including cell growth and proliferation, apoptosis, DNA repair, transcription and immune response. Defects in these pathways have been implicated in a number of human pathologies. Inhibition of the ubiquitin proteasome pathway by proteasome inhibitors may be a rational therapeutic approach for various diseases, such as cancer and inflammatory diseases. Many of the critical cytokine and chemokine mediators of the progression of rheumatoid arthritis are regulated by nuclear factor kappa B ( NF ‐κ B ). In peptidoglycan/polysaccharide‐induced polyarthritis, proteasome inhibitors limit the overall inflammation, reduce NF ‐κ B activation, decrease cellular adhesion molecule expression, inhibit nitric oxide synthase, attenuate circulating levels of proinflammatory cytokine interleukin‐6 and reduce the arthritis index and swelling in the joints of the animals. Since proteasome inhibitors exhibit anti‐inflammatory and anti proliferative effects, diseases characterized by both of these processes such as rheumatoid arthritis might also represent clinical opportunities for such drugs. The regulation of the proteasomal complex by proteasome inhibitors also has implications and potential benefits for the treatment of rheumatoid arthritis. This review summarizes the ubiquitin proteasome pathway, the structure of 26 S proteasomes and types of proteasome inhibitors, with their actions, and clinical applications of proteasome inhibitors in various diseases.